Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives

Cardiology Research and Practice
Akshyaya PradhanRishi Sethi

Abstract

Low-density lipoprotein lowering with statins has convincingly and consistently proven to reduce cardiovascular events in both primary and secondary prevention. However, despite high-dose statin therapy, residual cardiovascular risk remains and many patients also do not tolerate statins. Ezetimibe was initially projected as a frontline alternative to statin. It is an intestinal cholesterol absorption inhibitor with modest LDL lowering effects. But, major studies failed to demonstrate any beneficial effect of CV outcomes, and the drug was relegated to oblivion. IMPROVE-IT, a contemporary, large, and well-designed trial, unequivocally demonstrated reduction in CV outcomes with ezetimibe when added to statin therapy. The benefits are seen in both sexes, elderly, CKD, diabetes mellitus, and in patients with prior CABG. It also reduces biomarkers and induces plaque regression like statins. The drug has now established itself as an add-on therapy to statin when monotherapy fails to achieve LDL goals and when it is not tolerated. The combination therapy has excellent safety and efficacy record. It has now been endorsed by major guidelines too in management of dyslipidemia. Yes, ezetimibe can indeed improve cardiovascular outcomes!

References

Jun 1, 1997·Current Opinion in Lipidology·M W Huff, J R Burnett
Jun 24, 2004·Journal of General Internal Medicine·Jeffrey J EllisA Mark Fendrick
Aug 24, 2004·American Journal of Epidemiology·Melissa A AustinSteve E Humphries
Sep 24, 2004·The New England Journal of Medicine·Alan S GoChi-yuan Hsu
Aug 21, 2007·JAMA : the Journal of the American Medical Association·Sean M DonahoeElliott M Antman
Apr 10, 2008·JAMA : the Journal of the American Medical Association·Barbara V HowardJianhui Zhu
Sep 4, 2008·The New England Journal of Medicine·Anne B RossebøUNKNOWN SEAS Investigators
May 16, 2009·Journal of Clinical Pharmacology·Alejandra MeaneyEduardo Meaney
Nov 17, 2009·The New England Journal of Medicine·Allen J TaylorMark Turco
Feb 4, 2012·Journal of the American College of Cardiology·William J KostisJohn B Kostis
Apr 11, 2015·Archives of Medical Science : AMS·Maciej BanachDimitri P Mikhailidis
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Jun 22, 2015·American Heart Journal·Robin MathewsUNKNOWN TRANSLATE-ACS Study Investigators
Jan 30, 2016·Journal of the American College of Cardiology·Sabina A MurphyEugene Braunwald
May 22, 2016·Journal of the American Heart Association·Michelle L O'DonoghueMarc S Sabatine
Aug 30, 2016·European Heart Journal·Alon EisenUNKNOWN IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators
Feb 25, 2017·Journal of the American College of Cardiology·Erin A BohulaEugene Braunwald
Mar 18, 2017·Journal of the American College of Cardiology·Maria-Corina SerbanRobert S Rosenson
May 17, 2017·Journal of the American Society of Nephrology : JASN·John W StaniferMichael A Blazing
Jan 12, 2019·Circulation. Cardiovascular Quality and Outcomes·Ann Marie NavarMichael A Blazing
Aug 24, 2019·Journal of the American College of Cardiology·Arman QamarDavid A Morrow
Sep 11, 2019·European Heart Journal·François MachUNKNOWN ESC Scientific Document Group

❮ Previous
Next ❯

Methods Mentioned

BETA
imaging techniques

Software Mentioned

IMPROVE
ARBITER
IT

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.